Newronika

Focus: Newronika is an Italian biotech company specializing in adaptive deep brain stimulation (DBS) systems for neurological disorders, particularly Parkinson's Disease. The company operates as a focused medical device/neurotech innovator with a lean operational footprint.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Newronika

AI assessmentNot Hiring

No open roles listed right now. Follow Newronika to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

adaptive DBS delivered through AlphaDBS IPG System

Parkinson Disease

N/A

Clinical Trials (1)

NCT05262348An Open-label Clinical Trial to Compare the Safety and Effectiveness of Adaptive Versus Conventional Deep Brain Stimulation

N/A

Help build intelligence for Newronika

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneer a cutting-edge therapeutic modality (adaptive DBS) in an underserved neurology market with significant unmet need in Parkinson's management
Join a lean, specialized team where individual impact on device development and clinical strategy is directly visible and meaningful
Participate in early-stage company growth with potential for equity upside if adaptive DBS technology achieves clinical/commercial validation

Watch Out For

Currently zero active job openings suggests company is in stealth/early stage with limited hiring momentum and unclear career pathway expansion
Absence of funding, revenue, and employee count data indicates opacity on financial runway, stability, and organizational maturity—major red flags for employment security
No peer-reviewed publications (0 count) raises questions about clinical evidence generation and scientific credibility in a competitive neurotech landscape

Generated by Claude from Newronika's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

adaptive Deep Brain Stimulation

Parkinson Disease

N/A

Clinical Trials (1)

NCT03422757Safety and Efficacy of Adaptive DBS Vs Conventional DBS in Patients With Parkinson's Disease

N/A

Deep Brain Stimulation

Parkinson Disease, Idiopathic

N/A

Clinical Trials (1)

NCT06891781Investigating Adaptive Deep Brain Stimulation in Parkinson's Disease Management

N/A

AlphaDBS System

Parkinson Disease

N/A

Clinical Trials (1)

NCT04681534Safety and Efficacy of Adaptive Deep Brain Stimulation

N/A

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 4 clinical trials

Top TAs: Neurology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Neurology

4 pipeline

Marketed

Pipeline